Anaplastic lymphoma kinase: A glimmer of hope in lung cancer treatment?

Renato Franco, Gaetano Rocco, Federica Zito Marino, Giuseppe Pirozzi, Nicola Normanno, Alessandro Morabito, Pasquale Sperlongano, Paola Stiuso, Amalia Luce, Gerardo Botti, Michele Caraglia

Research output: Contribution to journalArticle

Abstract

Anaplastic lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7% of all non-small-cell lung cancers (NSCLCs) and represent an important molecular target for NSCLC treatment. The authors discuss the role of ALK-Rs in the prediction of clinical-pathological features of NSCLCs and the technical problems related to their determination in specimens. The authors also describe the preclinical and clinical results derived from the use of ALK inhibitors. ALK-R is generally detected in patients with specific clinical-pathological features: never-smokers, young males, adenocarcinoma histotype and EGF receptor/KRAS wild-type. The diagnosis of ALK-R remains a challenge, implicating the need of a careful filtering of patients. NSCLC patients harboring ALK-R have shown sensitivity to ALK inhibitors even if their activity is limited at the time by the occurrence of mechanisms of resistance. The authors summarize the strategies that in the future could overcome these mechanisms of escape.

Original languageEnglish
Pages (from-to)407-420
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Lung Neoplasms
Non-Small Cell Lung Carcinoma
Therapeutics
anaplastic lymphoma kinase
Epidermal Growth Factor Receptor
Adenocarcinoma

Keywords

  • anaplastic lymphoma kinase
  • crizotinib
  • lung cancer biology
  • lung cancer diagnosis
  • molecular biology
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Anaplastic lymphoma kinase : A glimmer of hope in lung cancer treatment? / Franco, Renato; Rocco, Gaetano; Marino, Federica Zito; Pirozzi, Giuseppe; Normanno, Nicola; Morabito, Alessandro; Sperlongano, Pasquale; Stiuso, Paola; Luce, Amalia; Botti, Gerardo; Caraglia, Michele.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 4, 04.2013, p. 407-420.

Research output: Contribution to journalArticle

Franco, R, Rocco, G, Marino, FZ, Pirozzi, G, Normanno, N, Morabito, A, Sperlongano, P, Stiuso, P, Luce, A, Botti, G & Caraglia, M 2013, 'Anaplastic lymphoma kinase: A glimmer of hope in lung cancer treatment?', Expert Review of Anticancer Therapy, vol. 13, no. 4, pp. 407-420. https://doi.org/10.1586/era.13.18
Franco, Renato ; Rocco, Gaetano ; Marino, Federica Zito ; Pirozzi, Giuseppe ; Normanno, Nicola ; Morabito, Alessandro ; Sperlongano, Pasquale ; Stiuso, Paola ; Luce, Amalia ; Botti, Gerardo ; Caraglia, Michele. / Anaplastic lymphoma kinase : A glimmer of hope in lung cancer treatment?. In: Expert Review of Anticancer Therapy. 2013 ; Vol. 13, No. 4. pp. 407-420.
@article{2edff2193f844d7ca8ef552097930d1c,
title = "Anaplastic lymphoma kinase: A glimmer of hope in lung cancer treatment?",
abstract = "Anaplastic lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7{\%} of all non-small-cell lung cancers (NSCLCs) and represent an important molecular target for NSCLC treatment. The authors discuss the role of ALK-Rs in the prediction of clinical-pathological features of NSCLCs and the technical problems related to their determination in specimens. The authors also describe the preclinical and clinical results derived from the use of ALK inhibitors. ALK-R is generally detected in patients with specific clinical-pathological features: never-smokers, young males, adenocarcinoma histotype and EGF receptor/KRAS wild-type. The diagnosis of ALK-R remains a challenge, implicating the need of a careful filtering of patients. NSCLC patients harboring ALK-R have shown sensitivity to ALK inhibitors even if their activity is limited at the time by the occurrence of mechanisms of resistance. The authors summarize the strategies that in the future could overcome these mechanisms of escape.",
keywords = "anaplastic lymphoma kinase, crizotinib, lung cancer biology, lung cancer diagnosis, molecular biology, non-small-cell lung cancer",
author = "Renato Franco and Gaetano Rocco and Marino, {Federica Zito} and Giuseppe Pirozzi and Nicola Normanno and Alessandro Morabito and Pasquale Sperlongano and Paola Stiuso and Amalia Luce and Gerardo Botti and Michele Caraglia",
year = "2013",
month = "4",
doi = "10.1586/era.13.18",
language = "English",
volume = "13",
pages = "407--420",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Anaplastic lymphoma kinase

T2 - A glimmer of hope in lung cancer treatment?

AU - Franco, Renato

AU - Rocco, Gaetano

AU - Marino, Federica Zito

AU - Pirozzi, Giuseppe

AU - Normanno, Nicola

AU - Morabito, Alessandro

AU - Sperlongano, Pasquale

AU - Stiuso, Paola

AU - Luce, Amalia

AU - Botti, Gerardo

AU - Caraglia, Michele

PY - 2013/4

Y1 - 2013/4

N2 - Anaplastic lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7% of all non-small-cell lung cancers (NSCLCs) and represent an important molecular target for NSCLC treatment. The authors discuss the role of ALK-Rs in the prediction of clinical-pathological features of NSCLCs and the technical problems related to their determination in specimens. The authors also describe the preclinical and clinical results derived from the use of ALK inhibitors. ALK-R is generally detected in patients with specific clinical-pathological features: never-smokers, young males, adenocarcinoma histotype and EGF receptor/KRAS wild-type. The diagnosis of ALK-R remains a challenge, implicating the need of a careful filtering of patients. NSCLC patients harboring ALK-R have shown sensitivity to ALK inhibitors even if their activity is limited at the time by the occurrence of mechanisms of resistance. The authors summarize the strategies that in the future could overcome these mechanisms of escape.

AB - Anaplastic lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7% of all non-small-cell lung cancers (NSCLCs) and represent an important molecular target for NSCLC treatment. The authors discuss the role of ALK-Rs in the prediction of clinical-pathological features of NSCLCs and the technical problems related to their determination in specimens. The authors also describe the preclinical and clinical results derived from the use of ALK inhibitors. ALK-R is generally detected in patients with specific clinical-pathological features: never-smokers, young males, adenocarcinoma histotype and EGF receptor/KRAS wild-type. The diagnosis of ALK-R remains a challenge, implicating the need of a careful filtering of patients. NSCLC patients harboring ALK-R have shown sensitivity to ALK inhibitors even if their activity is limited at the time by the occurrence of mechanisms of resistance. The authors summarize the strategies that in the future could overcome these mechanisms of escape.

KW - anaplastic lymphoma kinase

KW - crizotinib

KW - lung cancer biology

KW - lung cancer diagnosis

KW - molecular biology

KW - non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84876113722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876113722&partnerID=8YFLogxK

U2 - 10.1586/era.13.18

DO - 10.1586/era.13.18

M3 - Article

C2 - 23560836

AN - SCOPUS:84876113722

VL - 13

SP - 407

EP - 420

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 4

ER -